Ginkgo Bioworks (DNA) reported a third-quarter loss of $0.64 per share, missing the consensus estimate of -$0.58 by 10.3%. Revenue of $27.71 million beat the $20.5 million consensus by 35.2%. The loss narrowed sharply from a year ago, with earnings improving 55.9% year over year. Revenue fell 28.6% on Earnings Whispers' normalized basis. The quarter's central tension is that Ginkgo is finally turning its autonomous-lab pitch into named customers and its smallest losses yet, but the core revenue line is still shrinking. Part of the top-line beat also came from a one-time accounting item.

The revenue figures deserve care. The company's release compares $27.7 million with $29.4 million in the prior-year quarter, a 6% decline. That differs from the normalized 28.6% drop because the two figures use different comparison bases. Either way, revenue fell. The sequential jump from roughly $20 million in the second quarter looks strong, but management said a one-time cumulative catch-up on a modified long-term contract drove part of it. That makes the 35% beat less impressive than it appears. Nine-month revenue of $67 million is down 37%, or about 32% excluding Biomedit.

The cost story is more convincing. GAAP net loss from continuing operations fell to $41 million from $73 million a year earlier and from $76 million in the first quarter. Adjusted EBITDA improved to -$22 million from -$53 million. Segment R&D fell 48% to $27 million, and segment G&A fell 32% to $9 million. The EPS miss despite the revenue beat reflects factors below the operating line:

• a $2 million loss on an equity-method investment;
• interest income that fell to about $3 million from $5.7 million as the cash pile shrank;
• a share count that rose to roughly 64 million from 55.6 million, partly reflecting ongoing at-the-market equity sales.

Commercially, this was Ginkgo's most substantive quarter since it repositioned around autonomous labs. It sold its first autonomous lab to a big pharma company, Novo Nordisk, for Novo's new Waltham R&D site. A year ago, management had said it wanted exactly this kind of deal. The quarter also brought:

• a subcontract worth up to $17.5 million under an ARPA-H award, placing its RAC and Catalyst automation systems in RNA-medicine manufacturing;
• university lab commissions at Caltech, Maryland and Northwestern under the NSF's Programmable Cloud Laboratories program, plus an MIT Media Lab cloud lab;
• 22 new ADME customers in Cloud Lab, 20 of them new to Ginkgo;
• an Antibody Developability Consortium with AbbVie, Argenx, Lundbeck and others;
• a channel into Lilly's TuneLab platform;
• confirmed data purchases by frontier AI labs, including OpenAI.

Nebula, Ginkgo's in-house autonomous lab, has grown to 105 racks from about 36 planned a year ago. Management's tone was noticeably more confident. It pointed to a policy 'moment' that includes the Genesis Mission, the roughly $400 million NSF test bed and the $1.5 billion X-Labs initiative.

Bears still have legitimate ammunition. Ginkgo offers no revenue guidance and no 2027 outlook. Equipment revenue is recognized only at installation, typically 6 to 12 months after a booking, so the Novo and university wins will not appear in reported results for some time. Excess leased space still costs about $14 million a quarter. Cash and marketable securities have fallen to $285 million from $373 million in the first quarter and $462 million a year ago, and the company sold about $7 million of stock, net, through its at-the-market program during the quarter. The reaffirmed 2026 cash-burn guidance of $125 million to $150 million holds up. Nine-month burn of about $120 million leaves the company tracking toward the low-to-mid end of that range, and third-quarter burn fell to $27 million. Competition from established lab-automation vendors with entrenched pharma relationships remains a real risk.

The market had already priced in much of the story heading into the report. Shares closed at $11.65 before the release, up 25.4% from the open after the prior report and 35% above the 200-day moving average. However, they sit 36% below the 52-week high of $18.22 set on October 6, after a run from an August low of $6.47. That pattern suggests investors aggressively bid up the policy-driven narrative and then took profits. Investor sentiment stayed positive but cooled, slipping to 0.14 from 0.24. Earnings Whispers trend readings lean constructive, with price and AVWAP positive and sequential growth neutral.

The bottom line is that Ginkgo delivered real evidence that its autonomous-lab strategy is gaining traction, including a marquee pharma sale, government and university wins, and sharply narrower losses. It also kept its cash-burn guidance intact. The headline EPS miss matters less than the revenue picture. A one-time catch-up flattered the quarter, the underlying business is still contracting, and hardware bookings will take months to show up as revenue. With the cash balance still declining, the next several quarters must show the new customer pipeline converting into recurring revenue.